Literature DB >> 10729118

CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.

H Plotnicky-Gilquin1, A Robert, L Chevalet, J F Haeuw, A Beck, J Y Bonnefoy, C Brandt, C A Siegrist, T N Nguyen, U F Power.   

Abstract

We analyzed the protective mechanisms induced against respiratory syncytial virus subgroup A (RSV-A) infection in the lower and upper respiratory tracts (LRT and URT) of BALB/c mice after intraperitoneal immunization with a recombinant fusion protein incorporating residues 130 to 230 of RSV-A G protein (BBG2Na). Mother-to-offspring antibody (Ab) transfer and adoptive transfer of BBG2Na-primed B cells into SCID mice demonstrated that Abs are important for LRT protection but have no effect on URT infection. In contrast, RSV-A clearance in the URT was achieved in a dose-dependent fashion after adoptive transfer of BBG2Na-primed T cells, while it was abolished in BBG2Na-immunized mice upon in vivo depletion of CD4(+), but not CD8(+), T cells. Furthermore, the conserved RSV-A G protein cysteines and residues 193 and 194, overlapping the recently identified T helper cell epitope on the G protein (P. W. Tebbey et al., J. Exp. Med. 188:1967-1972, 1998), were found to be essential for URT but not LRT protection. Taken together, these results demonstrate for the first time that CD4(+) T cells induced upon parenteral immunization with an RSV G protein fragment play a critical role in URT protection of normal mice against RSV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729118      PMCID: PMC111852          DOI: 10.1128/jvi.74.8.3455-3463.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.

Authors:  E G Routledge; M M Willcocks; A C Samson; L Morgan; R Scott; J J Anderson; G L Toms
Journal:  J Gen Virol       Date:  1988-02       Impact factor: 3.891

2.  Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.

Authors:  D K Wagner; P Muelenaer; F W Henderson; M H Snyder; C B Reimer; E E Walsh; L J Anderson; D L Nelson; B R Murphy
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

3.  The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness.

Authors:  P R Johnson; P L Collins
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

4.  Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.

Authors:  E J Stott; G Taylor; L A Ball; K Anderson; K K Young; A M King; G W Wertz
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

5.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

6.  Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.

Authors:  E E Walsh; C B Hall; M Briselli; M W Brandriss; J J Schlesinger
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

7.  Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys.

Authors:  V G Hemming; G A Prince; W T London; P A Baron; R Brown; R M Chanock
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells.

Authors:  M J Cannon; E J Stott; G Taylor; B A Askonas
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

9.  Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen.

Authors:  R M Pemberton; M J Cannon; P J Openshaw; L A Ball; G W Wertz; B A Askonas
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

10.  Respiratory syncytial viral infection in children with compromised immune function.

Authors:  C B Hall; K R Powell; N E MacDonald; C L Gala; M E Menegus; S C Suffin; H J Cohen
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

View more
  14 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus.

Authors:  Negin Gitiban; Joseph A Jurcisek; Randall H Harris; Sara E Mertz; Russell K Durbin; Lauren O Bakaletz; Joan E Durbin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

6.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection.

Authors:  Jeong-Yoon Lee; Jun Chang
Journal:  J Microbiol       Date:  2017-10-27       Impact factor: 3.422

8.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

9.  CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).

Authors:  Monica M McNeal; John L VanCott; Anthony H C Choi; Matili Basu; Jason A Flint; Susan C Stone; John D Clements; Richard L Ward
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

10.  Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G).

Authors:  Kristi L Smiley; Monica M McNeal; Mitali Basu; Anthony H-C Choi; John D Clements; Richard L Ward
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.